The DOI matches its Crossref record; 67 of the 70 references it cites were found in a registry or an index.
The p75 Neurotrophin Receptor Promotes Amyloid-β(1-42)-Induced Neuritic Dystrophy In Vitro and In Vivo
Open accessAbstract
Oligomeric forms of amyloid-beta (Abeta) are thought to play a causal role in Alzheimer's disease (AD), and the p75 neurotrophin receptor (p75(NTR)) has been implicated in Abeta-induced neurodegeneration. To further define the functions of p75(NTR) in AD, we examined the interaction of oligomeric Abeta(1-42) with p75(NTR), and the effects of that interaction on neurite integrity in neuron cultures and in a chronic AD mouse model. Atomic force microscopy was used to ascertain the aggregated state of Abeta, and fluorescence resonance energy transfer analysis revealed that Abeta oligomers interact with the extracellular domain of p75(NTR). In vitro studies of Abeta-induced death in neuron cultures isolated from wild-type and p75(NTR-/-) mice, in which the p75(NTR) extracellular domain is deleted, showed reduced sensitivity of mutant cells to Abeta-induced cell death. Interestingly, Abeta-induced neuritic dystrophy and activation of c-Jun, a known mediator of Abeta-induced deleterious signaling, were completely prevented in p75(NTR-/-) neuron cultures. Thy1-hAPP(Lond/Swe) x p75(NTR-/-) mice exhibited significantly diminished hippocampal neuritic dystrophy and complete reversal of basal forebrain cholinergic neurite degeneration relative to those expressing wild-type p75(NTR). Abeta levels were not affected, suggesting that removal of p75(NTR) extracellular domain reduced the ability of excess Abeta to promote neuritic degeneration. These findings indicate that although p75(NTR) likely does not mediate all Abeta effects, it does play a significant role in enabling Abeta-induced neurodegeneration in vitro and in vivo, establishing p75(NTR) as an important therapeutic target for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other putative receptors/co-receptors involved in neuronal binding of Aβ oligomers include the p75 neurotrophin receptor (p75NTR) (Knowles et al., 2009), the receptor for advanced glycation end products (RAGE) (Sturchler et al., 2008), nicotinic acetylcholine receptors (Magdesian et al., 2005) and Frizzled (Magdesian et al., 2008).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Knowles et al., 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation
Coyle, J. T., Price, D. L., & DeLong, M. R. (1983) · Science · doi:10.1126/science.6338589 · Cited by 3,052
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452
Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer’s Disease
Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount, S. L., Raman, R., Davies, P., Masliah, E., Williams, D. S., et al. (2005) · Science · doi:10.1126/science.1105681 · Cited by 1,214
In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015
Sortilin is essential for proNGF-induced neuronal cell death
Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., Jacobsen, C., Kliemannel, M., Schwarz, E., Willnow, T. E., et al. (2004) · Nature · doi:10.1038/nature02319 · Cited by 962
Research works printed but not linked: 1
- 10.1172/JCI200523269 · DOI · Paper page
Cited by
Sorted by citations
Items 101–182 of 182
Yi, C., Goh, K. Y., Wong, L., Ramanujan, A., Tanaka, K., Sajikumar, S., & Ibáñez, C. F. (2020) · The EMBO Journal · doi:10.15252/embj.2020104450 · Cited by 20
Anzovino, A., Canepa, E., Alves, M., Lemon, N. L., Carare, R. O., & Fossati, S. (2023) · Cells · doi:10.3390/cells12242840 · Cited by 19
Stepanichev, M. Y., Лазарева, Н. А., Тухбатова, Г. Р., Salozhin, S. V., & Gulyaeva, N. V. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.11.013 · Cited by 19
Fading memories in aging and neurodegeneration: Is p75 neurotrophin receptor a culprit?
Wong, L., Wang, Z., Ang, S. R. X., & Sajikumar, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101567 · Cited by 19
Ovsepian, S. V., & Herms, J. W. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.005 · Cited by 19
Xiong, L., Chen, L., Deng, I. B., Zhou, X., & Wang, T. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15810 · Cited by 18
Zhan, X., Yao, J., Liu, D., Ma, Q., & Mei, Y. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12471 · Cited by 18
Implication of the neurotrophin receptor p75 NTR in vascular diseases: beyond the eye
Elshaer, S. L., & El‐Remessy, A. B. (2016) · Expert Review of Ophthalmology · doi:10.1080/17469899.2017.1269602 · Cited by 19
Zota, I., Chanoumidou, K., Charalampopoulos, I., & Gravanis, A. (2024) · Glia · doi:10.1002/glia.24505 · Cited by 17
Amyloid –β pathology in Alzheimer’s disease: A nano delivery approach
Meghana, G. S., Gowda, D., Chidambaram, S. B., & Osmani, R. A. M. (2023) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2023.103510 · Cited by 17
Nguyen, T. V., Crumpacker, R. H., Calderon, K., Garcia, F. G., Zbesko, J. C., Frye, J. B., Gonzalez, S., Becktel, D. A., Yang, T., Tavera-Garcia, M. A., et al. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000711 · Cited by 15
Self-citationTodd, K. L., Fossati, S., Ghiso, J. A., & Rostagno, A. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.09.010 · Cited by 15
Бобкова, Н. В., Vorobyov, V., Medvinskaya, N. I., Nesterova, I. V., Tatarnikova, O. G., Nekrasov, P. V., Samokhin, A. N., Деев, А. Д., Sengpiel, F., Koroev, D. O., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160146 · Cited by 14
Cognitive deficits are ameliorated by reduction in amyloid β accumulation in Tg2576/p75NTR+/− mice
Jian, C., Zou, D., Luo, C., Liu, X., Meng, L., Huang, J., Li, X., Huang, R., & Wu, Y. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.05.011 · Cited by 14
The Brain Cholinergic System in Neurodegenerative Diseases
Pepeu, G., Grossi, C., & Casamenti, F. (2014) · Annual Research & Review in Biology · doi:10.9734/arrb/2015/14623 · Cited by 13
Andrade‐Talavera, Y., Balleza‐Tapia, H., Dolz-Gaitón, P., Chen, G., Johansson, J., & Fisahn, A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01332-8 · Cited by 13
Kokkali, M., Karali, K., Thanou, E., Παπαδοπούλου, Μ., Zota, I., Tsimpolis, A., Efstathopoulos, P., Calogeropoulou, T., Li, K. W., Sidiropoulou, K., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02833-w · Cited by 13
Neurotrophins and Neurotrophin Receptors
Franco, M. L., Comaposada-Baró, R., & Vilar, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00005-5 · Cited by 12
Mouse genomic associations with in vitro sensitivity to simulated space radiation
Cekanaviciute, E., Tran, D., Nguyen, H., Macha, A. L., Pariset, E., Langley, S. A., Babbi, G., Malkani, S., Penninckx, S., Schisler, J. C., et al. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.07.006 · Cited by 12
Self-citationBrain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
Torres, M., Busquets, X., & Escribá, P. V. (2016) · InTech eBooks · doi:10.5772/64757 · Cited by 14
Cholinergic Reinforcement Signaling Is Impaired by Amyloidosis Prior to Its Synaptic Loss
Allard, S., & Shuler, M. G. H. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0967-23.2023 · Cited by 11
Ding, X., Wu, H., Ji, S., Cai, S., Dai, P.-W., Xu, M., Zhang, J., Zhang, Q.-X., Tian, Y., & Ma, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.16492 · Cited by 11
Role of amyloid β protein receptors in mediating synaptic plasticity
Li, Y., Sun, Z., Cao, Q., Chen, M., Luo, H., Lin, X., & Xiao, F. (2017) · Biomedical Reports · doi:10.3892/br.2017.863 · Cited by 11
Immune activation of the p75 neurotrophin receptor: implications in neuroinflammation
Danelon, V., Garrett-Thomson, S. C., Almo, S. C., Lee, F. S., & Hempstead, B. L. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1305574 · Cited by 10
Simmons, D. A., Alexander, N., Cao, G., Rippin, I., Lugassy, Y., Eldar-Finkelman, H., & Longo, F. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00495 · Cited by 10
Self-citationIto, S., Ménard, M., Atkinson, T. G., Brown, L., Whitfield, J., & Chakravarthy, B. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.09.015 · Cited by 10
Volpina, O. M., Medvinskaya, N. I., Kamynina, A. V., Запорожская, Я. В., Aleksandrova, I. Y., Koroev, D. O., Samokhin, A. N., Volkova, T. D., Arseniev, A. S., & Бобкова, Н. В. (2014) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162014040153 · Cited by 9
Cholinergic neurons—keeping check on amyloid β in the cerebral cortex
Ovsepian, S. V., & Herms, J. W. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00252 · Cited by 9
Ovsepian, S. V., O’Leary, V. B., Höschl, C., & Záborszky, L. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135895 · Cited by 9
Kelliny, S., Lam, H. Y., Parikh, A. R., Wang, Y., Bobrovskaya, L., Upton, R. N., & Zhou, X. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200502015203 · Cited by 9
Si, G., Volpina, O. M., Колыхалов, И. В., Fedorova, Y. B., Селезнева, Н. Д., Пономарева, Е. В., Koroev, D. O., & Kamynina, A. V. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20171178127-38 · Cited by 8
Marco-Salazar, P., Márquez, M., Fondevila, D., Rabanal, R. M., Torres, J. M., Pumarola, M. B., & Vidal, E. (2013) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2013.11.209 · Cited by 8
Devarajan, S., & Sharmila, D. J. S. (2014) · Advances in Bioinformatics · doi:10.1155/2014/736378 · Cited by 8
West, E., Osborne, C., Nolan, W., & Bate, C. (2015) · Biology · doi:10.3390/biology4020367 · Cited by 7
Li, H., Zou, J., Yao, Z., Yu, J., Wang, H., & Xu, J. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.11.007 · Cited by 6
Mustata, G.-M., Shekhawat, G. S., Lambert, M. P., Viola, K. L., Velasco, P. T., Klein, W. L., & Dravid, V. P. (2012) · Applied Physics Letters · doi:10.1063/1.3697682 · Cited by 6
Neuroprotective Strategies for Alzheimer’s Disease Prevention and Therapy
Simmons, D. A., Yang, T., Massa, S. M., & Longo, F. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00016-2 · Cited by 6
Self-citationNeurotrophin Receptor p75 mRNA Level in Peripheral Blood Cells of Patients with Alzheimer’s Disease
Xu, Y., Li, W., Wang, J., Zhu, C., Shen, Y., Shi, A., Zeng, G., Xu, Z., Zhou, X., & Wang, Y. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00035-9 · Cited by 6
Kraemer, B. R., Clements, R. T., Escobedo, C., Nelson, K., Waugh, C. D., Elliott, A. S., Hall, W. C., & Schemanski, M. T. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.036 · Cited by 6
Pinedo‐Vargas, L., Salcido, F. A. M., Lorea-Hernández, J. J., de Lafuente, V., & Peña‐Ortega, F. (2025) · Hippocampus · doi:10.1002/hipo.70017 · Cited by 5
Synthetic microneurotrophins: Neurotrophin receptors for therapeutics of neurodegenerative diseases
Zota, I., Calogeropoulou, T., Chanoumidou, K., Charalampopoulos, I., & Gravanis, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70143 · Cited by 5
Wu, J., Ma, H., Niu, X., Zhang, Z., Guo, R., Shen, N., Tian, Y., Zhao, H., Yang, Y., & Chen, Y. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103105 · Cited by 4
p75NTR is mainly responsible for Aβ toxicity but not for its internalization: a primary study
Yu, H., Yang, M., Wang, Y., Xiao, R., & Zhou, X. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0892-x · Cited by 4
Bradshaw, J. M., Nguyen, L., Wallace, W., Li, C., Sauer, J., Bard, F., & Bova, M. P. (2012) · Assay and Drug Development Technologies · doi:10.1089/adt.2011.398 · Cited by 4
Fogle, J. E., Hudson, L. C., Thomson, A., Sherman, B. L., Gruen, M. E., Lascelles, B. D. X., Colby, B., Clary, G., Longo, F. M., & Meeker, R. B. (2021) · Journal of NeuroVirology · doi:10.1007/s13365-021-00956-2 · Cited by 5
Self-citationA lifespan staging model of basal forebrain cholinergic vulnerability
Shanks, H. R. C., Chen, S., Onuska, K. M., & Schmitz, T. W. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71380 · Cited by 3
Yegla, B., & Parikh, V. (2015) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00254 · Cited by 3
Receptors | Neurotrophin Receptor Signaling
Kraemer, B. R., & Carter, B. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00310-8 · Cited by 3
Small molecules from Bacopa monneiri as potent inhibitors against Neurodegenerative DisordersPreprint
Sangeet, S., & Khan, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.31.486590 · Cited by 3
APP as an innate injury-response molecule
Olmsted, Z. T., & Sofroniew, M. V. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107361 · Cited by 3
Chanoumidou, K., Zota, I., Papadopoulou, M. A., Konstantinou, C., Tsimpolis, A., Tsagliotis, E., Tziortziou, M., Ntarntani, K., Grünewald, A., Lavigne, M. D., et al. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04965-y · Cited by 2
The aggregation of amyloid-β: from condensation, nucleation, and conformation to targeting therapy
Chen, B., Chen, T., Sun, Z., Liu, L., Jia, Y., Ji, Y., Wang, J., Sun, F., & Huang, Y. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124397 · Cited by 2
Neurochemical Aspects of Alzheimer Disease
Farooqui, A. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-15889-1_1 · Cited by 2
Tutorial on Drug Development for Central Nervous System
Yoon, H.-J., & Kim, J.-S. (2010) · Interdisciplinary Bio Central · doi:10.4051/ibc.2010.2.4.0009 · Cited by 1
The cholinotrophic system in Down syndrome
Mufson, E. J., & Perez, S. E. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19088-9.00017-2 · Cited by 1
Ma, Y., Xie, M., & Ibáñez, C. F. (2026) · Alzheimer s Research & Therapy · doi:10.1101/2025.10.28.685019 · Cited by 1
Li, X., Xie, M., & Ibáñez, C. F. (2026) · Journal of Neuroscience · doi:10.1523/jneurosci.1939-25.2026 · Cited by 1
Structure–Function mapping of the extracellular part of neurotrophin receptor P75
Бобкова, Н. В., Medvinskaya, N. I., Nesterova, I. V., Samokhin, A. N., Kamynina, A. V., Koroev, D. O., Volkova, T. D., Запорожская, Я. В., & Volpina, O. M. (2015) · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology · doi:10.1134/s1990747815020142 · Cited by 1
p75NTR: A Molecule with Multiple Functions in Amyloid-β Metabolism and Neurotoxicity
Shen, L., Zeng, F., Saadipour, K., Lu, J., Zhou, X., & Wang, Y. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_28-1 · Cited by 1
An Investigation on the Fundamental Interaction between Abeta Peptides and the AT-Rich DNA
Zhao, L. N., Zheng, J., Chew, L. Y., & Mu, Y. (2015) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b00957 · Cited by 1
Schliebs, R. (2013) · Springer eBooks · doi:10.1007/978-3-642-30574-0_51 · Cited by 1
p75NTR: A Molecule with Multiple Functions in Amyloid-β Metabolism and Neurotoxicity
Shen, L., Zeng, F., Saadipour, K., Lu, J., Zhou, X., & Wang, Y. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_28 · Cited by 1
Han, X., Xie, M., & Ibáñez, C. F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.20.683521 · Cited by 1
A possible physiological role of Abeta as a crosslinker
Blöchl, R. (2008)
Regulation of expression and cellular release of acetylcholinesterase
Hicks, D. A. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Keystone Symposium 2010 Highlights
Fagan, T. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101340
Regulation of the kinesin-3 motor, KIF1A, in a cellular model of Alzheimer’s disease
Akram, A. (2016) · Summit (Simon Fraser University)
New Small Molecule Drug Discovery for Alzheimer's Disease
Liu, K., Zhang, M., & Nagappan, G. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-6
Cortese, G. P. (2013) · CU Scholar (University of Colorado Boulder)
Yegla, B. (2016) · TUScholarShare (Temple University)
Potential Treatments for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00008-2 · Cited by 1
Si, G., Volpina, O. M., Колыхалов, И. В., Fedorova, Y. B., Селезнева, Н. Д., Пономарева, Е. В., Koroev, D. O., & Kamynina, A. V. (2019) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-019-00765-5
p75NTR: A Molecule with Multiple Functions in Amyloid-Beta Metabolism and Neurotoxicity
Wang, Y., Zeng, F., Saadipour, K., Lu, J., & Zhou, X. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_28
Alzheimer’s disease as a syndrome of overloaded amyloidic synaptic tagging in memory networksPreprint
Murphy, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/7gsaz
Alzheimer’s disease beyond the amyloid accumulation
Urkon, M., & Nagy, E. E. (2022) · Orvostudományi Értesítö · doi:10.2478/orvtudert-2022-0002
Hellström, S., Sajanti, A., Srinath, A., Bennett, C. M., Girard, R., Cao, Y. J., Frantzén, J., Koskimäki, F., Falter, J., Lyne, S. B., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12010112
Speidell, A. P., & Mocchetti, I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99744-7.00029-8
Baowan, 李. L., Mian, 谢. X., Wenhao, 刘. L., Weisong, 赵. Z., Haoyu, 李. L., & Changliang, 郭. G. (2025) · Laser & Optoelectronics Progress · doi:10.3788/lop251328
Liao, K., Xie, M., & Ibáñez, C. F. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03810-1
Early Retinal UCHL1 Dysregulation Coupled With Synaptic Loss Reflects Alzheimer's Disease Severity
Rentsendorj, A., Vit, J., Hutton, A., Koronyo, Y., Shahin, S., Robinson, E., Barrón, E., Rodriguez, A., Jallow, O., Sheyn, J., et al. (2026) · Advanced Science · doi:10.1002/advs.202600020
Targeting protein aggregate co-pathologies in neurodegeneration: a viable therapeutic strategy?
Buck, S. A., Madhavan, S. S., & Sanders, L. H. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00047-8
Metadata
- Authors
- Knowles, J. K., Rajadas, J., Nguyen, T.-V. V., Yang, T., LeMieux, M. C., Vander Griend, L., Ishikawa, C., Massa, S. M., Wyss-Coray, T., & Longo, F. M.
- Affiliations
- Stanford University (US)
- University of North Carolina at Chapel Hill (US)
- VA Palo Alto Health Care System (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Longo, Frank M.
- ORCID
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2009-08-26
- Volume
- 29
- Issue
- 34
- Pages
- 10627-10637
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC2771439
- OpenAlex
- W2090434536
- Cited by
- 184
- References
- 70
- Citations by year
- 2026: 10 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 9 · 2021: 14 · 2020: 11 · 2019: 11 · 2018: 4 · 2017: 10 · 2016: 17 · 2015: 14 · 2014: 17 · 2013: 15 · 2012: 12
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- U.S. Public Health Service (F30 NA051971)
- National Institute of Neurological Disorders and Stroke (F30NS051971)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- p75 neurotrophin receptor, amyloid-beta 42, Alzheimer's disease, neuritic dystrophy, amyloid-beta oligomers, c-Jun activation, cholinergic neurons, hippocampus, APP transgenic mice, therapeutic target
- MeSH terms
- Acetylcholinesterase, Alzheimer Disease, Analysis of Variance, Animals, Cell Survival, Cells, Cultured, Disease Models, Animal, Embryo, Mammalian, Enzyme-Linked Immunosorbent Assay, Exons, Hippocampus, Humans, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Nerve Degeneration, Neurons, Peptide Fragments, Spectrophotometry, Atomic, Amyloid beta-Peptides, Neurites, Prosencephalon, Amyloid beta-Protein Precursor, Receptor, Nerve Growth Factor, Fluorescence Resonance Energy Transfer, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review